(36 days)
Not Found
No
The description details a pneumatic compression device with a fixed, automatically timed cycle and pressure. There is no mention of adaptive behavior, learning, or any technology typically associated with AI/ML.
Yes
The device is intended to be used preventatively to increase venous blood flow in patients at risk of deep vein thrombosis, which is a therapeutic purpose.
No.
The Cirona™ 6100 system is a pneumatic compression device intended for the prevention of deep vein thrombosis by increasing venous blood flow, not for diagnosing a condition.
No
The device description explicitly states that the system consists of a pump, compression garments (sleeves), and extension tubing, which are all hardware components. While there is mention of "System Level Software Test" in the performance studies, the device is clearly a pneumatic compression device with physical components, not a software-only device.
Based on the provided information, the Cirona™ 6100 system is not an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use is to prevent deep vein thrombosis by increasing venous blood flow through pneumatic compression. This is a therapeutic and preventative action performed directly on the patient's body.
- Device Description: The device is a pneumatic compression system that applies pressure to the limbs. It does not involve the examination of specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or screening.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, using reagents, or providing diagnostic information based on laboratory tests.
IVD devices are specifically designed to be used in vitro (outside the body) to examine specimens and provide diagnostic or other information about a person's health. The Cirona™ 6100 operates in vivo (on the body) to physically manipulate blood flow.
N/A
Intended Use / Indications for Use
The Cirona™ 6100 system is a prescription device intended to be used preventatively to increase venous blood flow in patients at risk of deep vein thrombosis due to the associated risk factors for thrombus formation during: trauma, critical care, general medicine, general surgery, as well as neurological, orthopedic, urologic, obstetric conditions and treatments.
Product codes
JOW
Device Description
The Cirona™ 6100 deep vein thrombosis prevention system is a pneumatic compression device that noninvasively helps reduce the incidence of deep vein thrombosis, a potentially life threatening condition. The Cirona'' 6100 system consists of a pump, a pair of single patient reusable soft compression garment(s) (sleeves), and the extension tubing set for calf and calf-thigh. The device will alternatively inflate the two garments and mimic the natural walking pace in order to enhance circulation. The device supplied compression provides a 60-second automatically timed cycle consisting of an approximately 12-second inflation period followed by a 48-second period of relaxation. A pressure of 40mm Hg is used for both the calf and calf-thigh treatments. This pressurization enhances venous flow and fibrinolytic activity in order to ultimately prevent early blood clotting.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
limbs, calf, calf-thigh, legs
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Various bench and laboratory testing were performed and they assure that the product meets its specifications. The sleeve bladder burst test was performed to ensure sleeves are structurally sound during treatment and all sleeves tested maintained structural integrity at the highest pressure setting for anticipated maximum treatment time. The device passed all the tests listed below. The manufacturer believes that the technological characteristics of the Cirona™ 6100 are substantially equivalent to those of the predicate devices. The performance testing includes the following tests:
Test 1: System Level Software Test
Test 2: Pressure Accuracy
Test 3: Cycle Time Test
Test 4: Alarm Function Test
Test 5: Pressure Sensor Calibration Test
Test 6: Sleeve Bladder Burst Test
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
K961166, K991038, K090308, K010744
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.5800 Compressible limb sleeve.
(a)
Identification. A compressible limb sleeve is a device that is used to prevent pooling of blood in a limb by inflating periodically a sleeve around the limb.(b)
Classification. Class II (performance standards).
0
510(K) SUMMARY
APR 0 9 2013
Submitter:
Devon Medical Products.
Contact Person:
Ruth Wu, COO 1100 First Avenue, Suite 202
King of Prussia, PA 19406
Phone: 610.757.4103
610.930.4035 Fax:
Common Classification & Proprietary Names:
Intermittent Pneumatic Compression Device Common Names:
Cirona™ 6100 Proprietary Name:
Date Prepared:
December 6st, 2012
Classification
The classification name, 21 CFR Part and Paragraph number, product code and classification of the Cirona™ 6100.
|
ame | ---------------
. | .
| |
|-----------------------------------|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 1
ressible limh Slopvo | 270 5800 | | |
Predicate Devices:
The Cirona 6100 Deep Vein Thrombosis Prevention Therapy System is substantially equivalent to the following.
| Predicate Device | Manufacturer | 510(k)# |
|---|---|---|
| Flowtron Excel AC550 | HNE HEALTHCARE, INC | K961166 |
| VASO PRESS DVT SYSTEM, MODELS VP500, VP501 | BRITT CORP., INC | K991038 |
| RESTEP DVT SYSTEM, MODEL RSP-101 | STORTFORD MEDICAL LLC | K090308 |
| Flowtron Universal AC600 | HNE HEALTHCARE, INC | K010744 |
Device Description
The Cirona™ 6100 deep vein thrombosis prevention system is a pneumatic compression device that noninvasively helps reduce the incidence of deep vein thrombosis, a potentially life threatening condition. The Cirona'''' 6100 system consists of a pump, a pair of single patient reusable soft compression garment(s) (sleeves), and the extension tubing set for calf and calf-thigh. The device will alternatively inflate the two
1
garments and mimic the natural walking pace in order to enhance circulation. The device supplied compression provides a 60-second automatically timed cycle consisting of an approximately 12-second inflation period followed by a 48-second period of relaxation. A pressure of 40mm Hg is used for both the calf and calf-thigh treatments. This pressurization enhances venous flow and fibrinolytic activity in order to ultimately prevent early blood clotting.
Intended Use:
The Cironal " 6100 system is a prescription device intended to be used preventatively to increase venous blood flow in patients at risk of deep vein thrombosis due to the associated risk factors for thrombus formation during: trauma, critical care, general medicine, general surgery, as well as neurological, orthopedic, urologic, obstetric conditions and treatments.
Contraindications:
The Cirona™ 6100 system should NOT be used in the following conditions:
- · Severe atherosclerosis or other ischemic vascular diseases
- Suspected or known acute deep vein thrombosis
- · Severe congestive cardiac failure
- · Existing pulmonary edema
- · Existing pulmonary embolisms
- · Extreme deformity of the limbs
- · Any local skin or tissue condition in which the garments would interfere:
- · Gangrene
- Untreated or infected wounds
- Recent skin graft
- Dermatitis
- Known presence of malignancy in the legs
- · Limb infections, including cellulitis, that have not received antibiotic coverage
- · Presence of lymphangiosarcoma
Technological Characteristics:
The manufacturer believes that the technological characteristics of the Cirona™ 6100 are substantially equivalent to those of the predicate devices.
The Cironal 10 6100 has very similar components to its predicate devices and has very similar principles of operation. The device consists of an electrically generated source of compressed air; tubing to convey the pressurized air to the sleeve and, like the predicates, pressure is applied cyclically for 12 seconds inflated and 48 seconds deflated. The pressure delivered is 40mmHg.
2
Performance Testing
Various bench and laboratory testing were performed and they assure that the product meets its specifications. The sleeve bladder burst test was performed to ensure sleeves are structurally sound during treatment and all sleeves tested maintained structural integrity at the highest pressure setting for anticipated maximum treatment time. The device passed all the tests listed below. The manufacturer believes that the technological characteristics of the Cirona™ 6100 are substantially equivalent to those of the predicate devices. The performance testing includes the following tests:
| List of Performance Tests | ||
|---|---|---|
| Test 1 | System Level Software Test | |
| Test 2 | Pressure Accuracy | |
| Test 3 | Cycle Time Test | |
| Test 4 | Alarm Function Test | |
| Test 5 | Pressure Sensor Calibration Test | |
| Test 6 | Sleeve Bladder Burst Test |
Standards
The Cirona 10 6100 conforms to the following standards:
IEC 60601-1 2005 Medical electrical equipment - Part 1: General requirements for basic safety and essential performance
IEC 60601-1-2:2007 Medical electrical equipment -- Part 1-2: General requirements for basic safety and essential performance - Collateral standard:
AAMI ES 60601-1: 2012 Medical electrical equipment - Part 1: General requirements for basic safety and essential performance
ISO 14971:2007 Medical devices - Application of risk management to medical devices
ISO 10993-5:2009 Biological evaluation of medical devices, Part 5: Tests for in vitro cytotoxicity
ISO 10993-10: 2012 Biological evaluation of medical devices, Part 10: Tests for irritation and skin sensitization
ISO 10993-12: 2007 Biological evaluation of medical devices, Part 12: Biological evaluation of medical devices, Part 12: Sample preparation and reference materials
ANSI/ASQ Z1.9-2008 American National Standard: Sampling procedures and Tables for inspection by variables for percent nonconforming
3
Statement of Substantial Equivalence
The Cirona™ 6100 is substantially equivalent in technology, function, operating parameters, and intended use to predicate devices that are currently available and in distribution, and does not raise any new questions of safety or effectiveness.
Conclusions
In accordance with the Federal Food, Drug and Cosmetic Act and 21 CFR Part 807, and based on the information provided in this pre-market notification, Devon Medical Products, believes that the Cirona™ 6100, is substantially equivalent to the predicate devices as described herein.
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three curved lines representing its wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
April 9, 2013
Devon Medical, Inc. C/O Mr. Mark Job Regulatory Technology Services LLC 1394 25th Street NW Buffalo, MN 55313
Re: K130571
Trade/Device Name: Devon Cirona 6100 DVT Prevention System Regulation Number: 21 CFR 870.5800 Regulation Name: Compressible limb sleeve Regulatory Class: Class II Product Code: JOW Dated: February 28, 2013 Received: March 4, 2013
Dear Mr. Job:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
5
Page 2 - Mr. Mark Job -
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address.
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Matthew Gillillebrenner
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
INDICATIONS FOR USE STATEMENT
K130571 510(k) Number (if known):
Device Name: Cirona™ 6100 Deep Vein Thrombosis Prevention Therapy System
Indications for Use:
The Cirona™ 6100 system is a prescription device intended to be used preventatively to increase venous blood flow in patients at risk of deep vein thrombosis due to the associated risk factors for thrombus formation during: trauma, critical care, general medicine, general surgery, as well as neurological, orthopedic, urologic, obstetric conditions and treatments.
Prescription Use AND/OR (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)